As a regular feature of our annual forecast issue, IBO selects a firm from our industry as “company of the year.” In designating the company of the year, IBO recognizes an analytical and life science instrument maker that has accomplished technical, operational and financial achievements. Such achievements are a function of strong financial performance, market […]
Thermo and Life The pending merger (see IBO 4/15/13) will create an industry behemoth and creates new challenges for competitors, such as those in the lab distribution market. It also will provide Thermo with a commanding position as a supplier to pharmaceutical and biotechnology companies for both instruments and consumables. The integration process will be […]
R&D spending by US universities declined 3.3% in fiscal year 2012 (FY12) in constant 2005 dollars to $34.6 billion—the first decline in 38 years. Adjusted for inflation, federal government academic R&D spending fell 1.6% to $40,130 million. However, excluding the federal government, R&D spending by US universities rose 4.7% to $25,644 million adjusted for inflation. […]
R&D spending by two thousand of the world’s largest companies grew 6.2% in fiscal 2012 to more than €538.8 billion ($690.8 billion = €0.78 = $1), with 70% of the companies increasing R&D expenditures, according to the recently published The 2012 EU Industrial R&D Investment Scoreboard. This compares to 6.2% growth for these companies in […]
Along with its 2013 Scoreboard, the EU also published a survey of industrial R&D trends. The survey is based on responses from 172 EU Scoreboard companies, which collectively spend €62 billion ($79 billion = €0.78 = $1) on R&D. The respondents expect their R&D expenditures to increase an average of 2.6% from 2013 to 2015. […]
R&D spending by large pharmaceutical companies is stabilizing despite continued restructuring. However, as pharmaceutical companies continue to streamline R&D, resources are shifting to clinical trials. Forced to balance between cost containment and drug development to secure future revenues, companies are prioritizing investments in drugs with the strongest growth potential, especially for therapies that will both […]
Economic reforms in Japan have put science and technology at center stage. Under Prime Minister Shinzo Abe, who was elected last year, the country has embarked on a new economic policy termed “abenomics” that is designed to spur growth via government stimulus, monetary infusion through new central banking policies and structural changes. The plan aims […]
Beverly, MA and Boulder, CO 9/6/13—Enzymatics, a producer of reagents, kits and assays, has acquired ArcherDx, a developer of kits and software for next generation sequencing (NGS) for use in investigating cancer treatments, for cash, equity and potential milestones worth up to $50 million. Enzymatics stated that the acquisition expands its Enzymatics Diagnostics group, adding […]
Milford, MA 8/19/13—SeraCare Life Sciences has purchased Kirkegaard & Perry Laboratories (KPL) for an undisclosed amount. KPL develops antibodies and related reagents for life science research and diagnostics. The acquisition will expand SeraCare’s offerings for developing IVD assays. “SeraCare strives to facilitate its customers’ product development efforts, allowing researchers to focus on the science, specifically […]
Austin, TX 8/7/13; Washington, DC 7/7/13—Luminex has announced a restructuring plan, including a 5% reduction in its workforce. The plan will affect the Assay and Related Products’ Newborn Screening Group, as well as the company’s Brisbane, Australia, office, which will be closed. The changes are expected to result in annualized cost savings of $5–$6 million, […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
